76716-51-3

Usage

Uses

Used in Pharmaceutical Industry:
4-(Benzyloxy)piperidine is used as a building block and intermediate for the synthesis of pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
4-(Benzyloxy)piperidine is utilized as a reagent in the production of agrochemicals, such as pesticides and herbicides, due to its potential applications in enhancing crop protection and yield.
Used in Material Science:
4-(Benzyloxy)piperidine is employed in the field of material science for the synthesis of advanced materials with specific properties, such as polymers, coatings, and adhesives, leveraging its unique chemical structure and reactivity.
Overall, 4-(Benzyloxy)piperidine's diverse applications across industries like pharmaceuticals, agrochemicals, and material science highlight its significance as a versatile compound in modern chemical research and development.

Upstream product

• 95798-23-5 1-(benzyloxycarbonyl)-4-hydroxypiperidine 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 159557-47-8 4-benzyloxypiperidine-1-carboxylic acid tert-butyl ester 
• 165754-27-8 4-benzyloxy-N-(benzyloxycarbonyl)piperidine 

Downstream Products

• 872692-35-8 N-tert-butoxycarbonyl-L-valine 4-benzyloxypiperidide 
• 872692-21-2 L-valine 4-(benzyloxy)piperidide 
• 872692-22-3 N-(2-ethoxycarbonyl)-L-valine 4-(benzyloxy)piperidide 
• 420136-65-8 6-(4-Benzyloxypiperidin-1-carbonyl)-3H-furo[3',2':4,5]benzo[1,2-d]oxazole-2-one 

Relevant academic research and scientific papers

Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Aβ1-42 aggregation for Alzheimer's disease therapeutics

With the goal of developing Alzheimer's disease therapeutics, we have designed and synthesized new piperidine derivatives having dual action of acetylcholinesterase (AChE) and beta-amyloid peptide (Aβ) aggregation inhibition. For binding with the catalytic site of AChE, an ester with aromatic group was designed, and for the peripheral site, another aromatic group was considered. And for intercalating amyloid-beta oligomerization, long and linear conformation with a lipophilic group was considered. The synthetic methods employed for the structure with dual action depended on alcohols with an aromatic ring and the substituted benzoic acids, which are esterificated in the last step of the synthetic pathway. We screened these new derivatives through inhibition tests of acetylcholinesterase, butyrylcholinesterase (BChE), and Aβ1-42 peptide aggregation, AChE-induced Aβ1-42 aggregation. Our results displayed that compound 12 showed the best inhibitory potency and selectivity of AChE, and 29 showed the highest selectivity of BChE inhibition. Compounds 15 and 12 had inhibitory activities against Aβ1-42 aggregation and AChE-induced Aβ aggregation. In the docking model, we confirmed that 4-chlorobenzene of 12 plays the parallel π-π stacking against the indole ring of Trp84 in the bottom gorge of AChE. Because the benzyhydryl moiety of 12 covered the peripheral site of AChE in a funnel-like shape, 12 showed good inhibitory potency against AChE and could inhibit AChE-induced Aβ1-42 peptide aggregation.

Asymmetric michael reactions on polymeric support: Auxiliary immobilization and stereoselective construction of quaternary stereocenters

Several strategies for the immobilization of a L-valine-derived auxiliary on a Merrifield resin and on poly(ethylene glycol) are reported. The latter is shown to work excellently in asymmetric copper(II)-catalyzed Michael reactions of cyclic β-oxo esters 2 with methyl vinyl ketone (4), yielding the corresponding addition products 5 with quaternary stereocenter in selectivities of 97-99 % ee. The PEG-supported auxiliary 1d can be precipitated from diethyl ether solutions and reused. A sulfur-containing β-oxo ester 2c was prepared in 92 % yield by a DMAP-catalyzed transesterification method in order to detect enamine formation on solid support. The sulfur content can be used as an additional parameter in combustion analysis and therefore, may act as a diagnostic probe for enamine formation. Wiley-VCH Verlag GmbH & Co. KGaA, 2005.

Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use

The subject invention provides compounds having the structure: 1 wherein,R1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra;R2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra, orR1, R2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH2)2OH or —CH2C(═O)OH;R3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C1-C15)alkyl, (C1-C15)alkoxy, or —NRaRb;R4 is hydrogen or substituted or unsubstituted (C1-C15)alkyl;R5 is —(CH2)mOR6, —CHNOR7, —C(═O)NR8R9, —(CH2)mC(═O)OR10, —(CH2)kC(═O)NR11R12;wherein R6 is a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring;R7 is hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl;R8 and R9 are each independently hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl, (C1-C30)alkylamino, (C1-C30)alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, orR8, N, and R9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring;R10 is hydrogen or a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or heterocyclic ring;R11, N and R12 together form a 4-8 membered heterocyclic ring;Ra and Rb are each independently hydrogen or alkyl;m is 0, 1, 2 or 3; andk is 1, 2 or 3,or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.

Chemoselective deprotection of teriary benzylamines and reduction of carbon-carbon double bonds in the presence of benzyl and benzyloxymethyl ethers

Catalytic transfer hydrogenation using 10% Pd-C in the presence of 1,4-cyclohexadiene as the hydrogen donor selectively debenzylates amines and reduces carbon-carbon double bonds while leaving benzyl and benzyloxymethyl ethers intact. (C) 2000 Elsevier Sc

Azetidine, pyrrolidine and piperidine derivatives

A class of substituted azetidine, pyrrolidine and piperidine derivatives, linked by a fluoro-substituted alkylene chain to a fused bicyclic heteroaromatic moiety such as indolyl, are selective agonists of 5-HT1 -like receptors, being potent ago

Benzimidazole derivatives

The invention is directed to substituted benzimidazole compounds which are ligands for dopamine receptor subtypes used in the treatment of the dopamine system.

A novel type of Pd/C-catalyzed hydrogenation using a catalyst poison: Chemoselective inhibition of the hydrogenolysis for O-benzyl protective group by the addition of a nitrogen-containing base

A mild and chemoselective hydrogenation method for a variety of reducible functional groups distinguishing front aliphatic and aromatic' benzyl ethers was accomplished by the addition of an appropriate nitrogen- containing base to the Pd/C-catalyzed hydrogenation system.

Selective Inhibition of Benzyl Ether Hydrogenolysis with Pd/C Due to the Presence of Ammonia, Pyridine or Ammonium Acetate

Ammonia, pyridine and ammonium acetate were found to be extremely effective as inhibitors of Pd/C catalyzed benzyl ether hydrogenolysis.While olefin, Cbz, benzyl ester and azide functionalities were hydrogenated smoothly, benzyl ethers were not cleaved in the presence of these additives.